Covestor Ltd Has $134,000 Position in Humana Inc. (NYSE:HUM)

Covestor Ltd lifted its stake in Humana Inc. (NYSE:HUM) by 59.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 387 shares of the insurance provider’s stock after acquiring an additional 144 shares during the quarter. Covestor Ltd’s holdings in Humana were worth $134,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of HUM. Rakuten Securities Inc. bought a new stake in shares of Humana during the 4th quarter worth approximately $25,000. Gradient Investments LLC increased its holdings in Humana by 200.0% during the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after buying an additional 40 shares during the last quarter. Cetera Trust Company N.A bought a new stake in Humana during the fourth quarter worth $28,000. Private Wealth Management Group LLC acquired a new stake in Humana in the fourth quarter valued at $32,000. Finally, Carolinas Wealth Consulting LLC grew its position in shares of Humana by 274.1% in the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock valued at $46,000 after acquiring an additional 74 shares during the period. Institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

HUM has been the topic of a number of recent analyst reports. Morgan Stanley initiated coverage on Humana in a research report on Monday, June 24th. They set an “equal weight” rating and a $374.00 price target on the stock. Jefferies Financial Group dropped their price objective on shares of Humana from $411.00 to $381.00 and set a “buy” rating on the stock in a research report on Monday, April 22nd. Baird R W raised shares of Humana to a “hold” rating in a report on Thursday, May 30th. Bank of America increased their price target on shares of Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a report on Monday, May 20th. Finally, UBS Group reduced their price objective on Humana from $334.00 to $326.00 and set a “neutral” rating for the company in a report on Thursday, April 25th. Fourteen analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Humana currently has a consensus rating of “Hold” and an average target price of $402.05.

Humana Price Performance

NYSE:HUM traded up $0.70 during mid-day trading on Wednesday, reaching $386.57. The stock had a trading volume of 330,375 shares, compared to its average volume of 1,742,791. The stock has a 50-day simple moving average of $363.52 and a two-hundred day simple moving average of $347.00. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. Humana Inc. has a 12 month low of $298.61 and a 12 month high of $530.54. The stock has a market capitalization of $46.58 billion, a PE ratio of 24.02, a P/E/G ratio of 2.23 and a beta of 0.51.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. The company had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. Humana’s revenue was up 10.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $9.38 EPS. On average, equities analysts anticipate that Humana Inc. will post 16.27 earnings per share for the current year.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.